Drug-induced liver injury secondary to tirzepatide
Year: 2026
Type: article
Study design: Case Report
Abstract: Tirzepatide is a dual gastric inhibitory polypeptide and glucagon-like peptide-1 receptor agonist, used for the treatment of type 2 diabetes mellitus and obesity. While gastrointestinal side effects are well described in the literature, hepatotoxicity is not a recognised complication. Recent case reports have emerged describing drug-induced liver injury associated with tirzepatide. We present a case of a woman aged in her 20s who developed acute hepatocellular injury within four weeks of commencing tirzepatide. Extensive investigations did not reveal an alternative cause of liver injury. Following the cessation of tirzepatide, the patient demonstrated clinical and biochemical recovery over the following four weeks.
Source: BMJ Case Reports
Institutions: Griffith University, Gold Coast Hospital, Bond University
Language: English
Subfield: Pharmacology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7148888937